{"organizations": [], "uuid": "aee95051660555fbe5f88c09626f62605df99796", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-idera-pharma-files-definitive-prox/brief-idera-pharma-files-definitive-proxy-statement-over-with-pending-merger-with-biocryst-idUSFWN1RF072", "country": "US", "domain_rank": 408, "title": "BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T15:36:00.000+03:00", "replies_count": 0, "uuid": "aee95051660555fbe5f88c09626f62605df99796"}, "author": "", "url": "https://www.reuters.com/article/brief-idera-pharma-files-definitive-prox/brief-idera-pharma-files-definitive-proxy-statement-over-with-pending-merger-with-biocryst-idUSFWN1RF072", "ord_in_thread": 0, "title": "BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-idera pharma", "sentiment": "negative"}, {"name": "biocryst", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "idera pharmaceuticals inc", "sentiment": "none"}, {"name": "biocryst reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2, 2018 / 12:39 PM / Updated 2 minutes ago BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst Reuters Staff \nApril 2 (Reuters) - Idera Pharmaceuticals Inc : \n* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS \n* ‍BOARD OF DIRECTORS RECOMMEND THAT ALL STOCKHOLDERS VOTE “FOR” MERGER PROPOSAL AS WELL AS ALL OTHER IDERA PROPOSALS​  ", "external_links": [], "published": "2018-04-02T15:36:00.000+03:00", "crawled": "2018-04-02T15:48:36.007+03:00", "highlightTitle": ""}